Hinge Health Stock (HNGE) Q2 2026 Earnings: Revenue +53%, Cost To Serve +15%

Hinge Health (HNGE) Q2 2026 — Q2 2026 (3 months ended June 30, 2026): revenue $212.8M, up 53%, a 5.6% BEAT and 9.1% above the company's own $195M guide. Non-GAAP diluted EPS $0.59 vs a $0.615 bar - a 4.1% MISS. GAAP diluted EPS $0.52. Non-GAAP operating income $61.5M, up 136%, a 29% margin. The 8-K was accepted 4:08pm ET, AFTER the close: the reaction session was Wed Aug 5 at +1.73% ($79.42 to $80.79), then $80.08 Thursday - and then $89.33 Friday, up 11.55% on the heaviest volume of the week, three sessions after the print. Hinge Health grew revenue 53% and grew the cash cost of delivering that care 15.5%. Ninety-five cents of every incremental revenue dollar arrived as gross profit. That is the quarter, and it sits in the one line item that can prove the automation thesis: cost of revenue. Ignore the headline - GAAP gross margin going 70% to 86% is an SBC artifact, because last year's cost of revenue carried $16.4M of IPO stock compensation. The honest move is 83% to 87%. Then look at the equity: $151.3M of cash went out against stock in the half, and shares outstanding still went UP 1.30%, against 11.9M shares of unvested RSU and PRSU overhang. THE CALL: HOLD (3/5, FAIR VALUE $88 vs THE $89.33 CLOSE - 1.5% BELOW THE PRICE AND 8% BELOW WALL STREET) — base-case value ~$88.0 vs ~$89.33 today. KEY METRICS: - CALL: HOLD 3/5, fair value $88 vs the $89.33 Aug 7 close = 1.5% downside. Bull $117, bear $48. Buy under $76. Market cap $7.21B on 80.69M shares; no debt, $475.6M cash, EV $6.73B = 7.8x guided 2026 revenue of $858M and 28.1x guided non-GAAP operating income of $240M - 56.1x owner earnings after charging $78M of stock pay and taxing at 24%. - Street: Buy. 16 analysts, 15 buy / 1 hold / 0 sell, target $95.38 (median $96, range $65-$125). Citizens JMP raised to $107, Wells Fargo to $103, Needham to $97, all Aug 2026. What to watch: UP: revenue $212.8M, +53% against a +40% guide, and 9.1% above the company's own number; non-GAAP cost of revenue up only 15.5%, a 95.0% incremental gross margin; non-GAAP operating margin 19% to 29% in one year; full-year revenue guidance raised $57M against a $17.8M beat, so $39.2M is incremental - we tried to falsify that and failed; LTM billings running 1.20x revenue; no debt and $475.6M of cash; 15 of 16 analysts rate it a Buy. DOWN: EPS actually MISSED, $0.59 vs $0.615; the 70%-to-86% gross margin headline is a stock-compensation artifact and the real move is four points; sales and marketing grew 51.5%, so the go-to-market has NOT levered; $151.3M spent against stock and the share count rose 1.30%; free cash flow is running well ahead of earnings and $115.6M of the half is a deferred revenue build; and it is 56x owner earnings 0.7% off its 12-month high. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.